title: [Values of Detecting the Levels of β2-MG, TNF-α, CRP, IL-6 in the Patients with Multiple Myeloma].
abstract: OBJECTIVE
  To explore the values of detecting the serum levels of β2-MG, TNF-α, CRP, IL-6 in the patients with multiple myeloma.
  
  
  METHODS
  A total of 40 patents with multiple myeloma were included in the experiment group, and 40 healthy volunteers were selected as the control group. The levels of β2-MG, TNF-α, CRP and IL-6 were detected and compared in 2 groups, the different durie-salmon (DS) stages of β2-MG, TNF-α, CRP and IL-6 in the experiment group were analyzed.
  
  
  RESULTS
  The levels of β2-MG, CRP, IL-6 in the experiment group were higher than those in control group (P < 0.05); the level of TNF-α in the experiment group was lower than that in control group (P < 0.05); the levels of β2-MG, CRP, IL-6 at stage I, II, III in the experiment group was higher than those in control group (P < 0.05); the level of TNF-α at stage I, II, III in the experiment group was lower than that in the control group (P < 0.05); the levels of β2-MG, CRP, IL-6 at stage I, II, III in the experiment group displayed an increasing tendency, the levels of TNF-α at stage I, II, III in the experiment group displayed a declining trend (P < 0.05); the levels of β2-MG, CRP, IL-6 in the experiment group after treatment for 8, 16 weeks were higher than those in control group (P < 0.05); the level of TNF-α in the experiment group after treatment for 8, 16 weeks was lower than that in control group (P < 0.05); the levels of β2-MG, CRP and IL-6 in the experiment group after treatment for 16 weeks were lower than those for 8 weeks (P < 0.05); the levels of TNF-α in the experiment group after treatment for 16 weeks were higher than those for 8 weeks (P < 0.05). The levels of APE1 after treatment in the experiment group were lower than that before treatment.
  
  
  CONCLUSIONS
  The serum levels of β2-MG, TNF-α, CRP and IL-6 can be as index for diagnosis of multiple myeloma, can effectively evaluate the disease severity; their combination with APE1 expression level can evaluate the therapeutic efficacy; thus the detection of above-mentioned indexes is possessed of higher value for clinical applications.
authors.affiliation: Department of Hematology, Nanyang Central Hospital of Henan Province, Nanyang 473009, Henan Province, China.
authors.forename: Li-Juan
authors.initials: LJ
authors.lastname: Duan
authors.affiliation: Department of Hematology, Nanyang Central Hospital of Henan Province, Nanyang 473009, Henan Province, China.
authors.forename: Chao
authors.initials: C
authors.lastname: Li
authors.affiliation: Department of Hematology, Nanyang Central Hospital of Henan Province, Nanyang 473009, Henan Province, China. E-mail: 1034066216@qq.com.
authors.forename: Ru-Yu
authors.initials: RY
authors.lastname: Yang
mesh_terms: D002097:C-Reactive Protein / Q000378:metabolism*; D016022:Case-Control Studies; D006801:Humans; D015850:Interleukin-6 / Q000097:blood*; D009101:Multiple Myeloma / Q000097:blood* / Q000175:diagnosis; D014409:Tumor Necrosis Factor-alpha / Q000097:blood*; D001613:beta 2-Microglobulin / Q000097:blood*
chemical_list: C508600:IL6 protein, human; D015850:Interleukin-6; C439524:TNF protein, human; D014409:Tumor Necrosis Factor-alpha; D001613:beta 2-Microglobulin; D002097:C-Reactive Protein